Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Catarina D. Campbell
BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade With Dabrafenib, Trametinib, and Panitumumab in Patients With Colorectal Cancer
Clinical Cancer Research
Cancer Research
Oncology
Association ofMTORMutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism
JAMA Neurology
Neurology
Related publications
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
Clinical Cancer Research
Cancer Research
Oncology
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
Frontiers in Oncology
Cancer Research
Oncology
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Clinical Cancer Research
Cancer Research
Oncology
Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma
Oncologist
Cancer Research
Medicine
Oncology
Redifferentiation of Iodine-Refractory BRAF V600e-Mutant Metastatic Papillary Thyroid Cancer With Dabrafenib
Clinical Cancer Research
Cancer Research
Oncology
Prevalence of KRAS, BRAF, PI3K and EGFR Mutations Among Asian Patients With Metastatic Colorectal Cancer
Oncology Letters
Cancer Research
Oncology
Granulomatosis With Polyangiitis in a Patient Treated With Dabrafenib and Trametinib for BRAF V600E Positive Lung Adenocarcinoma
BMC Cancer
Cancer Research
Oncology
Genetics
Comment on “ERK and P38MAPK Combine to Improve Survival in Patients With BRAF Mutant Colorectal Cancer”
British Journal of Cancer
Cancer Research
Oncology
BRAF Mutant Colorectal Cancer: ErbB2 Expression Levels as Predictive Factor for the Response to Combined BRAF/ErbB Inhibitors
BMC Cancer
Cancer Research
Oncology
Genetics
